All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
More information on our cookie policy.
BioWorld. Link to homepage.
Powering insights from Cortellis. Link to Cortellis page on Clarivate website.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Special reports
Artificial intelligence
Coronavirus
Diagnosing the state of COVID-19 testing
Drugs to Watch 2020
The next pandemic
Premium reports
BioWorld Financings Reports
Disease Forecast Reports
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, January 27, 2021
Home
» FDA approves IND for phase I study of PD1-Vaxx in NSCLC
FDA approves IND for phase I study of PD1-Vaxx in NSCLC
Published at: Nov. 3, 2020
No Comments
Article reprints
Source:
https://science.bioworld.com/ddn/article.do?id=174686
BioWorld Science
Related Articles
FDA approves IND for phase IIb study of orismilast in patients with plaque psoriasis
FDA approves IND for phase IIa study of JNJ-40411813 in epilepsy